The top U.S. health official is calling for all alcoholic beverages to carry a warning label about cancer risk.

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.

Although we don't know a lot about the causes of Alzheimer's disease, the following conditions may raise your risk.

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the ...

Hmm: Depleted energy levels affect us all. But here's when they could indicate something serious. In 2024, the American ...

Symptom improvement with novel therapies and better patient-reported outcomes, as well as breakthrough hemolysis control, are among the paroxysmal nocturnal hemoglobinuria highlights from ASH 2024.

Laboratory studies uncover a simple yet promising approach to enhance personalized cell therapy. A dietary supplement may ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases ...

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...